

1 *covid19.Explorer*: A web application and R 2 package to explore United States COVID-19 3 data

4 Liam J. Revell^{1,2}

5 ¹Department of Biology, University of Massachusetts Boston, Boston, Massachusetts
6 02125

7 ²Facultad de Ciencias, Universidad Católica de la Santísima Concepción, Concepción,
8 Chile

9 Corresponding author:

10 Liam J. Revell^{1,2}

11 Email address: liam.revell@umb.edu

12 ABSTRACT

13 Appearing at the end of 2019, a novel virus (later identified as SARS-CoV-2) was characterized in the
14 city of Wuhan in Hubei Province, China. As of the time of writing, the disease caused by this virus
15 (known as COVID-19) has already resulted in close to 3 million deaths worldwide. SARS-CoV-2 infections
16 and deaths, however, have been highly unevenly distributed among age groups, sexes, countries, and
17 jurisdictions over the course of the pandemic. Herein, I present a tool (the *covid19.Explorer* R package
18 and web application) that has been designed to explore and analyze publicly available United States
19 COVID-19 infection and death data from the 2020/21 U.S. SARS-CoV-2 pandemic. The analyses and
20 visualizations that this R package and web application facilitate can help users better comprehend the
21 geographic progress of the pandemic, the effectiveness of non-pharmaceutical interventions (such as
22 lockdowns and other measures, which have varied widely among U.S. states), and the relative risks
23 posed by COVID-19 to different age groups within the U.S. population. The end result is an interactive
24 tool that will help its users develop an improved understanding of the temporal and geographic dynamics
25 of the SARS-CoV-2 pandemic, accessible to lay people and scientists alike.

26 INTRODUCTION

27 In 2019, a novel infectious disease was identified in Wuhan, a city of approximately 11 million residents
28 located in the Hubei Province of central China. This infectious disease, called *Coronavirus disease 2019*,
29 or COVID-19 (Velavan and Meyer, 2020), is now known to be caused by the previously unidentified
30 *severe acute respiratory syndrome coronavirus 2* or SARS-CoV-2 (Wong et al., 2020). Following the
31 Wuhan outbreak, cases of SARS-CoV-2 infection and COVID-19 death were subsequently identified in
32 Europe, the United States, and (by the time of writing) at least 192 countries worldwide. Counting from
33 the beginning of this global pandemic, there have been over 2.8 million confirmed COVID-19 deaths,
34 more than 560,000 of which have occurred in the United States alone (CDC, 2021).

35 R (R Core Team, 2020) is a powerful scientific computing environment and programming language
36 that is used by statisticians, data scientists, academic researchers, and students worldwide. I have built
37 a multifunctional R package (*covid19.Explorer*) and corresponding web application ([https://covid19-
38 explorer.org](https://covid19-explorer.org)). The purpose of both is to aid scientists and lay people alike to better understand the 2020/21
39 SARS-CoV-2 pandemic in the United States. Although my focus is on U.S. COVID-19 data, readers from
40 other countries might also be interested in the project – for instance, because the seasonal dynamics of
41 infection or the age distribution of mortality has been broadly similar among different affected areas of
42 the globe.

43 This R package and website is not designed to be a substitute or replacement for the many other
44 excellent software products and web tools that have been developed over the past year (e.g., Brown et al.
45 2020; Johns Hopkins University 2020; Reiner et al. 2020; Gu 2020). It nonetheless contains a number of

46 different analytical approaches and methods that distinguish it from other software and web resources.
47 For example, the *covid19.Explorer* R package is the only software that I know of that allows the user
48 to specify a custom model of the infection fatality ratio (IFR, the fraction of all SARS-CoV-2 infected
49 individuals that ultimately die of COVID-19 in a given population; Blackburn et al. 2021) through time
50 and then uses this model to reconstruct daily SARS-CoV-2 infections. Although this strategy has been
51 employed by other modelers to estimate daily SARS-CoV-2 infections throughout the pandemic (most
52 notably, perhaps, by Gu 2020 – though other modeling groups also use confirmed daily COVID-19 deaths
53 as an important lagging indicator of new infections, e.g., Reiner et al. 2020), mine is, so far as I am aware,
54 the only software that puts this model of IFR entirely under user control.

55 Likewise, the *covid19.Explorer* R package and website includes visualization methods not available
56 in other software or web resources. For instance, the *covid19.Explorer* can create a plot of U.S. state-wise
57 daily estimated infections in aggregate that is unlike any graphical representation of United States SARS-
58 CoV-2 infection data that I have encountered in other software, webpages, or media sources. Similarly, the
59 package includes an ‘iceberg graph’ showing daily observed SARS-CoV-2 infections above the waterline,
60 and estimated unobserved infections below it. I have likewise never encountered a precisely identical
61 visual representation of the U.S. COVID-19 pandemic data in other electronic resources or software.

62 Lastly, it’s perhaps important to mention one thing that the *covid19.Explorer* R package most
63 adamantly *does not* do, and that is make predictions about the future. There are numerous different
64 individual scientists and research teams that have dedicated enormous effort and resources to predicting
65 the epidemic dynamics of SARS-CoV-2 in the United States and globally (e.g., Reiner et al. 2020; Gu
66 2020) with widely varying success (e.g., Chin et al. 2020; Ioannidis et al. 2020; James et al. 2021).
67 The *covid19.Explorer* R package and site have the more modest goal of helping users develop a better
68 understanding of what *has* happened over the course of the United States SARS-CoV-2 pandemic from its
69 beginnings to the present day.

70 1 METHODS

71 1.1 Preamble

72 *covid19.Explorer* is a library of functions and data that can be loaded and run using the R scientific
73 computing software (R Core Team, 2020). The *covid19.Explorer* package is open source and freely
74 available from its GitHub page (<https://github.com/liamrevell/covid19.Explorer/>). The *covid19.Explorer*
75 package in turn depends on the CRAN R packages *maps* (Becker et al., 2018), *phytools* (Revell, 2012),
76 *randomcoloR* (Ammar, 2019), and *RColorBrewer* (Neuwirth, 2014).

77 Though the *covid19.Explorer* R package can be downloaded, installed, and run from R on its own,
78 it has primarily been designed to be utilized via a web portal: <https://covid19-explorer.org>. This web
79 portal was built in the integrated development environment *Rstudio* (RStudio Team, 2020), using the
80 web application development system *shiny* (Chang et al., 2021). In addition to those R libraries already
81 mentioned, the web application also uses the package *shinyWidgets* (Perrier et al., 2021).

82 The data used by the various applications of the *covid19.Explorer* are all publicly available and were
83 obtained (unless otherwise indicated) from the *United States Centers for Disease Control and Prevention*
84 *National Center for Health Statistics* (<https://www.cdc.gov/nchs/>; henceforward, the CDC) or the *United*
85 *States Census Bureau* (<https://www.census.gov/>). In particular, these data consist of: provisional U.S.
86 COVID-19 death counts by sex, age, and week from the CDC; United States confirmed COVID-19 cases
87 and deaths by state through time from the CDC; weekly counts of deaths by jurisdiction and age group
88 from the CDC, 2015-present; weekly counts of deaths by state and select causes (including COVID-19)
89 from 2014-2018, 2019-2020, and 2020-2021 from the CDC; estimated population sizes by U.S. state and
90 by age, from 2010-2019 from the Census Bureau; and, finally, the geographic center of each U.S. state (to
91 be used for mapping visualizations).

92 1.2 Types of functions in *covid19.Explorer*

93 The *covid19.Explorer* R package (and corresponding web application) consists of two main types of
94 functions.

95 The first of these (exemplified by the *shiny* web application webpage tabs denominated *U.S. COVID-19*
96 *infections*, *Iceberg plot*, *State comparison*, *Plausible range*, and *Infection estimator*) consists of functions
97 that are designed to estimate the true number of COVID-19 infections over the course of the pandemic.
98 Since there are a variety of reasons that the true number of infections (rather than simply the number of

confirmed cases) is of interest, these various aforementioned applications of the *covid19.Explorer* package are all designed to help users apply a model (of their own design, see below) to estimate the daily number of new infections, the plausible range of new infections, the cumulative number of infections, or the daily or cumulative infections as a percentage of the total population or per 1M persons.

Each of these *covid19.Explorer* applications uses a model – but it is one whose parameters are set by the user, rather than estimated from the data. In particular, users of the *covid19.Explorer* package or corresponding web interface will need to specify: (1) a value or set of values for the infection fatality ratio, IFR (Roques et al., 2020), of SARS-CoV-2 infection through time; and (2) an average lag time from infection to death. The values for each of these model parameters have been default values that are fairly reasonable, as detailed in the sections below; however, users are nonetheless strongly encouraged to apply multiple values and examine the sensitivity of their results. (In fact, this is one of the main purposes of the project!)

The second type of function (exemplified by the web application tabs *Deaths by age*, *Excess mortality by age*, and *By state*) do not employ an explicit model and exist primarily to permit the user to interact directly with CDC COVID-19 death and 2020 excess mortality data, to understand the implications of these data, and to generate interesting or useful data visualizations.

The names and corresponding web application tabs of all functions in *covid19.Explorer* are given in alphabetical order in Table 1, below.

Table 1. A summary of the functions and corresponding web applications that currently make up the *covid19.Explorer* R package.

Function name	Application tab	Description
<i>age.deaths</i>	Excess mortality by age	Graph weekly or cumulative excess mortality by age and jurisdiction.
<i>compare.infections</i>	State comparison	Compare daily or cumulative deaths and estimated daily or cumulative infections between states and U.S. jurisdictions.
<i>covid.deaths</i>	Deaths by age	Plot weekly or cumulative confirmed COVID-19 deaths by age group and compared to all deaths.
<i>iceberg.plot</i>	Iceberg plot	Graph observed daily confirmed SARS-CoV-2 cases (above the ‘waterline’ of the graph) and estimated unobserved infections (below it).
<i>infection.estimator</i>	Infection estimator	Estimate daily or cumulative SARS-CoV-2 infections based on observed deaths and confirmed cases.
<i>infection.range.estimator</i>	Plausible range	Estimate the plausible range of daily or cumulative infections based on an interval of IFR values at each time point.
<i>infections.by.state</i>	SARS-CoV-2 infections	Visualize geographic distribution of new or cumulative SARS-CoV-2 infections through time.
<i>state.deaths</i>	By state	Graph weekly or cumulative excess deaths by U.S. state.
<i>updateData</i>	Not applicable	Update the data used by <i>covid19.Explorer</i> from the web.

1.3 Estimating infections

Since the beginning of this pandemic, it has been widely understood that confirmed COVID-19 cases underestimate the true number of infections, sometimes vastly (Al-Sadeq and Nasrallah, 2020; Wu et al., 2020). This underestimation has multiple causes. One important factor is that there has been limited testing capacity throughout much of the SARS-CoV-2 pandemic in the United States, but particularly when the pandemic was in its earliest days (Rosenberg et al., 2020). A second significant factor affecting the disconnect between observed cases and true infections are the facts that in the United States SARS-

124 CoV-2 testing is voluntary, population surveillance testing has been relatively scarce, and many cases
125 of SARS-CoV-2 infection present asymptotically or with mild symptoms (Oran and Topol, 2020). As
126 such, I consider confirmed COVID-19 deaths to be a much more reliable indicator of disease burden than
127 confirmed cases. Deaths, however, are obviously a *lagging* indicator of infections.

128 The key parameter that relates daily COVID-19 deaths to the number of infections is the infection
129 fatality ratio (also called the *infection fatality rate* or *IFR*). IFR, normally expressed as a percent, is defined
130 as the fraction of deaths among all infected individuals, taking into account both observed infections
131 ('cases') and asymptomatic or unobserved infections (O'Driscoll et al., 2020). An IFR value of 1.5%, for
132 example, would mean that, on average, for every 1,000 infections in a specified population, there would
133 be 15 deaths.

134 I modeled the number of new SARS-CoV-2 infections on the i th day by taking the number of observed
135 COVID-19 deaths on day $i + k$ (in which k is the average lag period between initial infection and death,
136 where death is the outcome of infection), and then dividing this quantity by the infection fatality rate,
137 IFR. In other words, given 50 COVID-19 deaths on day $i + k$, and an IFR of 0.5%, we would predict that
138 10,000 new SARS-CoV-2 infections *had occurred* on day i . Both k , the average lag time from infection to
139 death (in cases of SARS-CoV-2 infections resulting in death), and the IFR are to be specified by the user.




Figure 1. a) Observed U.S. daily COVID-19 deaths (red bars) and user-specified infection fatality rate (IFR) function (blue line) through time. b) Ratio of daily estimated infections over confirmed SARS-CoV-2 infections (grey points) and fitted sigmoid function of the implied case detection rate (CDR) through time.

140 A fairly reasonable lag time between infection and death might be approximately three weeks. (Not to
141 be confused with the median lag time between symptom offset and death, e.g., Wilson et al. 2020.) For
142 example, during a large outbreak in Melbourne, Australia the time difference between the peak recorded
143 cases and peak confirmed COVID-19 deaths was around 17 days. Infected persons normally test negative
144 for the first few days following exposure (Kucirka et al., 2020), so this more or less corresponds with a
145 three week lag.

146 Likewise, IFR values ranging from about 0.2% to over 1.0% have been reported over the course of the

147 pandemic. For instance, a study based on an early, super-spreader event in Germany estimated an IFR
148 (corrected to the demographic distribution of the local population) of 0.36% (Streeck et al., 2020). Other
149 researchers have reported higher estimated IFR (e.g., Rinaldi and Paradisi 2020). In a large meta-analysis
150 O’Driscoll et al. (2020) estimated IFR of SARS-CoV-2 infection across 45 different countries and obtained
151 median estimates ranging from 0.24% to 1.49%, with higher IFRs typically reported for countries with
152 older populations. In general, it is probably reasonable to suppose that IFR has fallen through time
153 as treatment of severely ill patients has improved (Fan et al., 2020). Likewise, even within the U.S.,
154 IFR is unlikely to be precisely the same at a given date in different jurisdictions, due to differences in
155 demographic structure between areas as well as other factors.

156 I suspect that it is within reason for users of *covid19.Explorer* to specify an IFR that is no greater than
157 about 1.5% and that declines gradually from the start of the pandemic towards the present, with a *current*
158 IFR that is perhaps around 0.3% - 0.5% (O’Driscoll et al., 2020; Blackburn et al., 2021). Nonetheless,
159 *covid19.Explorer* permits the user to specify a time-varying IFR by fixing the IFR at each quarter (on
160 the website), or at any arbitrary time interval (using the R package directly), and then interpolating daily
161 IFR between each period using local regression smoothing (LOESS; Cleveland 1979). As such, it is
162 also possible to build a model for IFR through time that both falls *and* rises, perhaps as stresses on local
163 decrease or increase through time with rising and falling COVID-19 case numbers.

164 Reporting can vary through time including regularly over the course of the week. (For instance,
165 fewer COVID-19 deaths tend to be reported on the weekends compared to Monday through Friday; e.g.,
166 Figure 1.) To take these reporting artifacts into account I used both moving averages and local regression
167 (LOESS) smoothing. Both the window for the moving average and the LOESS smoothing parameter are
168 controlled by the user.

169 The approach of using only confirmed COVID-19 deaths – though robust – does not permit us to
170 estimate the true number of infections between k days ago and the present. To do this, I assumed a
171 sigmoidal relationship between time and the ratio of confirmed cases over the true number of infections (a
172 quantity called the case detection rate or CDR; Figure 1). Since the number of confirmed cases cannot
173 exceed the true number of new infections, logic dictates that the CDR should have a value that falls
174 between 0 and 1.

175 I decided on a sigmoidal relationship between the case detection rate and time because it seemed
176 reasonable to presume the ratio was very low early in the pandemic when confirming a new infection
177 was limited primarily by testing capacity, but that CDR has probably risen (in many localities) to a more
178 or less consistent value as testing capacity increased. Since getting tested is voluntary, and since many
179 infections of SARS-CoV-2 are asymptomatic or only mildly symptomatic, this ratio seems unlikely to rise
180 to very near 1.0 in the U.S. regardless of the availability of testing.

181 Figure 1, created using *covid19.Explorer*, shows daily estimated infections (under our model) /
182 confirmed cases for all U.S. data over the entire course of the pandemic to date in panel Figure 1b, given
183 observed daily deaths (red bars) and assumed IFR evolution through time (blue curved line) of panel
184 Figure 1a. Our plot seems to show a CDR of about 0.42 at the present; however, the reader should keep in
185 mind that in practice this value is estimated separately for each jurisdiction that is being analyzed, and as
186 such might be lower in some states and higher in others, even for a constant IFR value or function.

187 In the event that a sigmoid function did not fit well to the implied daily CDR for a given state or
188 jurisdiction, I simply substituted the mean CDR from the last 100 days of data. Since I only used the CDR
189 to estimate daily infections for the most recent time period of our data (see below), and since CDR tended
190 to increase asymptotically towards a more or less constant value in most jurisdictions (e.g., Figure 1), this
191 seemed fairly reasonable.

192 After fitting this sigmoidal curve to our observed and estimated cases through now $-k$ days, we then
193 must turn to the last period. To obtain estimated infections for these days, we merely divide our observed
194 cases from the last k days of data by the fitted CDR values of our curve. Figure 2 shows the result of this
195 analysis applied to data for the U.S. state of Massachusetts.

196 In addition to computing the raw number of daily infections, this method can also be used to compute
197 infections as a percentage of the total population. To make this calculation, I obtained state populations
198 through time from the U.S. Census Bureau. Data was only given through 2019 at the time of writing, so
199 to estimate state-level 2020 population sizes, I used a total mid-year 2020 U.S. population estimate of
200 331,002,651) to ‘correct’ each 2019 state population size to a 2020 level.

201 Finally, CDC mortality data splits New York City (NYC) from the rest of New York state. Since




Figure 2. a) Observed daily COVID-19 deaths and an assumed model of IFR in which the infection fatality ratio is initially high (1.5%), but then declines and stabilizes at around 0.6% through the present day. b) Estimated daily infections (green), cases (blue), and deaths (red).

202 this contrast is interesting (e.g., Gonzalez-Reiche et al. 2020), I maintained the separation – and used
203 a mid-2019 population estimate of (8,336,817) for NYC, then simply assumed that the population of
204 NYC has changed between 2015 and 2020 in proportion to the rest of the state. (Since they have a part
205 : whole relationship, this seemed pretty reasonable. In fact, according to the U.S. Census Bureau from
206 2010 to 2019 the fraction of New York State residents living in New York City is estimated to have grown
207 by around 0.1% per year, from 41.8% in 2010 to about 42.8% in 2019. If this trend continued through
208 2020, then I may have underestimated the population of New York City by about 0.2%. Since this is only
209 relevant when considering per capita SARS-CoV-2 infections and COVID-19 deaths, I suspect it is a
210 relatively minor source of error compared to other simplifying assumptions of this study.)

211 **1.4 Assumptions about estimating infections**

212 This model is very simple. In using it, we start by merely imagining that if we knew the true number of
213 infections and the IFR for our population of interest on day i , then we could predict the number of deaths
214 on day $i + k$, in which k is the lag-time from infection to death (for SARS-CoV-2 infections leading to
215 death). Having observed the deaths, and supposing a particular value of IFR for day i , we can likewise
216 work backwards and reconstruct the most plausible number of infections on that day.

217 Although the model does not pre-suppose a specific value or function for IFR, it does require that
218 one be specified by the user. As such, it is probably worth mentioning the effect of setting an IFR value
219 that is either too high or too low compared to the (invariably unknown) *true* IFR for the population
220 of interest. An IFR that is too high (overall or at a specific time during the pandemic) will have the
221 general effect of causing us to systematically underestimate the number of infections that have occurred.
222 This makes sense because if we imagine observing 50 COVID-19 deaths, an IFR of 0.5% would imply
223 that these deaths correspond to a total of 10,000 SARS-CoV-2 infections. By contrast, a higher IFR
224 of, say, 1.0% would instead imply that only 5,000 infections had occurred. Assuming an IFR value

225 that is too low will (obviously) have exactly the opposite effect and thus cause us to overestimate the
226 number of infections that have occurred. The default values for IFR through time specified in the web
227 portal (<https://covid19-explorer.org>) are 0.85% on Feb. 1, 2020 and then declining every 3 months:
228 0.65%, 0.55%, 0.5%, and 0.5% on January 31, 2021, with intermediate values interpolated using LOESS
229 smoothing.

230 The purpose of the software and web resource is to allow the user to explore alternative (reasonable)
231 scenarios for IFR through time and examine their effects on estimated daily or cumulative SARS-CoV-2
232 infections in different jurisdictions; however, the default values are not arbitrary. First, they are largely
233 consistent with population-wise IFR estimates from seroprevalence research (e.g., O’Driscoll et al. 2020).
234 Second, they yield estimated daily infections that are qualitatively if not quantitatively similar to those
235 obtained by several other leading models of the SARS-CoV-2 pandemic in the United States (e.g., Gu
236 2020; Reiner et al. 2020).

237 I also assume a homogeneous value of k at any particular time. In fact, literature sources report
238 lag-times between two and eight weeks (e.g., Yang et al. 2020). Nonetheless, I suspect that inferences by
239 this method should not be badly off – so long as the true IFR does not swing about wildly from day to day,
240 and so long as the number of deaths is not extremely few for any reporting period.

241 I likewise assume a constant lag-period, k , through time. This assumption is perhaps a bit more
242 dubious as it seems quite reasonable to suppose that, for a specific state or jurisdiction, as IFR falls k
243 might also increase. If k increased as a function of time, this would mean that recent peaks in daily new
244 infections would be systematically biased forward in time (that is, they occurred earlier than it seems)
245 compared to peaks that occurred early in the pandemic. (The converse would also be true if k decreased
246 rather than increasing through time.) This is a complexity that I explicitly chose to ignore in the model.

247 I assume that a more or less consistent fraction of COVID-19 deaths are reported as such – that is,
248 that COVID-19 is neither systematically under- or overreported as the cause of death at any point during
249 the course of the pandemic. A violation of this assumption is not quite as grave as it might seem, however,
250 because it can simply be ‘baked in’ to our model for IFR. For instance, if we think that COVID-19 deaths
251 were under-reported near the start of the pandemic (e.g., Weinberger et al. 2020), perhaps due to limited
252 testing capacity, this can be accommodated into our model for daily infections simply by specifying a
253 slightly lower IFR value for SARS-CoV-2 infection at that time (keeping in mind, of course, that the true
254 IFR has generally decreased through time; e.g., Levin et al. 2020).

255 In estimating the number of daily infections from k days ago to the present, we assume that the
256 relationship between time (since the first infections) and the ratio of confirmed and estimated infections
257 (i.e., the case detection rate, CDR) is sigmoidal in shape (Figure 1). This is a testable assumption that
258 seems to hold fairly well across the entire U.S. (Figure 1) and for some jurisdictions, but less well for
259 others. It is equally plausible to suspect that CDR could shift not only as a function of time, but also as
260 demands on testing capacity rise and fall with case numbers, or as different populations become infected.
261 This should be the subject of additional study, but my suspicion is that this would not be likely to have a
262 large effect on our model compared to other simplifications.

263 One slightly problematic possibility is that the true CDR in the most recent k days is much lower or
264 higher than estimated CDR. This could happen if, for example, in jurisdictions with low surveillance
265 testing, changes in the demographic distribution of new SARS-CoV-2 infections (due to, for instance,
266 age-prioritized vaccination) mean that relatively few infections present symptomatically and get tested.
267 This would have the effect of causing CDR to be overestimated and would result in a concomitant
268 *underestimation* of daily new SARS-CoV-2 towards the right side of the graph. The opposite effect is
269 expected if surveillance testing was to be increased (for instance, in a jurisdiction with high numbers of
270 in-person college or university students simultaneously returning to campus), thus increasing true CDR
271 relative to its estimated value in the most recent period compared to time periods prior to k days before
272 the present.

273 Finally we assume no or limited reporting delay. This is obviously incorrect. There are two main
274 sources of reporting delay: the delay between when an individual is infected and when they go on to
275 test positive for SARS-CoV-2; and the delay between when an infected patient dies and their death is
276 reported to the CDC. Given this delay in reporting, a more precise interpretation of the estimated number
277 of daily infections, is a (rough) estimate of the number of new individuals who would be reported as
278 testing positive for SARS-CoV-2 on any given day under a hypothetical scenario of universal daily testing.




Figure 3. Iceberg plot showing the confirmed daily new infections (above the ‘waterline’ of the plot) and estimated unobserved infections (below it) for New York state.

279 **1.5 Showing observed and estimated unobserved infections using an ‘iceberg plot’**

280 As noted above, it has long been well-understood that the number of daily confirmed COVID-19 cases is
281 an underestimate of the true number of daily SARS-CoV-2 infections, sometimes by a very wide margin
282 (Wu et al., 2020). To visualize this phenomenon, I devised an iceberg plot in which we simultaneously
283 graph the number of observed infections (above the ‘waterline’ of the graph) and the estimated number of
284 unobserved SARS-CoV-2 infections (below it). Figure 3 gives this analysis for New York state, in which I
285 assumed the same IFR model through time as was used to generate Figures 1 and 2.

286 **1.6 Mapping the distribution of infections across states**

287 A hallmark feature of the U.S. COVID-19 pandemic has been the shifting geographic distribution
288 of infections through time among states. To capture this dynamic, I devised a plotting method for
289 *covid19.Explorer* in which I overlay the daily or cumulative SARS-CoV-2 infections under our model
290 (outlined above), separated by state.

291 For this visualization, I selected a geographic color palette such that RGB color values were made
292 to vary as a function of latitude, longitude, and (arbitrarily) geographic distance from Florida. This is
293 intended to have the effect of making the regional geographic progression of infection more apparent in
294 the graph. The result can be seen in Figures 4 and 5.

295 This plotting method shares all the assumptions of our infection estimator, above, but adds the
296 additional assumption that our model of IFR is the same for all states. This assumption is quite dubious,
297 in fact, as IFR could be expected to rise in locations where hospital resources are overtaxed by high disease
298 burden; and, conversely, fall in hospitals where staff have more experience in treating COVID-19 patients.

299 On an individual level, IFR is also very strongly influenced by age (e.g., O’Driscoll et al. 2020), as
300 well as by other risk factors such as obesity (e.g., Kompaniyets et al. 2021) and socioeconomics (e.g.,
301 Lone et al. 2021). As such, even if IFR falls through time in different jurisdictions in a similar way, one
302 would nonetheless expect to observe higher IFR in states with higher median age, higher obesity, or higher
303 poverty rates, compared to younger, less obese, and higher median income states. Although I do not doubt
304 that these nuances are important in making specific, quantitative statements about the particular number
305 of infections in each state, I nonetheless believe that my method is effective at visually capturing the
306 overall geographic dynamics of the COVID-19 pandemic in the United States.

307 One point that may be worth noting about this lattermost assumption is that use of a constant IFR
308 model across all U.S. states does not, in and of itself, have the effect of distorting the *total* number of




Figure 4. Daily estimated infections separated by state.

309 estimated new infections on each day. To see this, let's start by imagining (for instance) 3,000 infections
310 in jurisdiction A on day 1 and 30 resultant deaths k days later (IFR of 1.0%). Meanwhile, perhaps,
311 2,000 infections have occurred in jurisdiction B on day 1, but only 10 deaths k days later (IFR of 0.5%).
312 Using the global IFR of $(30 + 10) / (3,000 + 2,000) \times 100\% = 0.8\%$ gives us the same estimate of the
313 total number of new infections on day 1 ($40 / 0.008 = 5,000$) whether it is applied to each jurisdiction
314 separately, or applied to the total number of deaths together. What *is* affected, however, are the proportions
315 of new infections attributed to each jurisdiction. In the constant IFR model the number of infections
316 attributed to jurisdiction A ($30 / 0.008 = 3,750$) would be too few; while the number of new infections
317 attributed to jurisdiction B ($10 / 0.008 = 1,250$) is too many. Thus the distribution of daily new infections
318 among sites, but not their grand total across jurisdictions, can be affected by an assumption that the IFR
319 of SARS-CoV-2, and the way that it changes through time, is the same across all of the jurisdictions in
320 our dataset.

321 1.7 Visualizing COVID-19 mortality data

322 In addition to modeling the number of infections through time, the *covid19.Explorer* R package and
323 website also allows users to visualize the distribution of COVID-19 deaths by age and sex, as well as
324 mortality in excess of normal during 2020 compared to other recent years (2015-2019).

325 Excess mortality (also called *mortality displacement*; e.g., Huynen et al. 2001) is defined as the
326 number of deaths (for any period) in excess of the 'normal' number of deaths for the same period. To
327 compute the raw death counts for each jurisdiction, I tabulated the 2015-2018 counts with the 2019-2020
328 provisional counts. To correct observed deaths in prior years to 2020 levels, I simply multiplied the
329 past-year death tally by the ratio the jurisdiction population in 2020 compared to the population in the
330 past year. Finally, to compute excess deaths for any jurisdiction, I then took the death counts (or corrected
331 death counts) for 2020, and subtracted the mean of years 2015 through 2019. This treats 2015 through
332 2019 as 'normal' years, and 2020 as unusual.

333 One factor that I did not account for in this lattermost calculation is movement of people between
334 jurisdictions. In fact, some studies indicate that the COVID-19 pandemic has disrupted normal immigration
335 patterns of humans (e.g., Smith and Wesselbaum 2020). Areas harder-hit by SARS-CoV-2 may have
336 experienced a net loss of residents (even apart from direct mortality due to COVID-19) due to emigration
337 of people from the affected jurisdiction, or reduced immigration to the area (Smith and Wesselbaum,
338 2020). Fortunately, the *covid19.Explorer* R package and web application will be easy to update when
339 final census and estimated population sizes for the states and jurisdictions of my dataset are published for
340 2020 and 2021.

341 1.8 The *covid19.Explorer* web interface

342 Though the *covid19.Explorer* package can be used within an interactive R session, it has also been
343 interfaced to the web by way of the web application that I developed in Rstudio (RStudio Team, 2020)
344 using the *shiny* web development system (Chang et al., 2021). The *covid19.Explorer* web application is
345 hosted at the website <https://covid19-explorer.org>.

346 Figure 5 shows a screenshot of this web application, illustrating an analysis of the estimated cumulative
347 number of SARS-CoV-2 infections through time across U.S. states. In this web application, the user
348 must specify the value of IFR at the beginning of each three month period, and that at the end of the year,
349 beginning on Feb. 1, 2020, and ending on Jan. 31, 2021. Values on these intervals are interpolated using
350 LOESS smoothing.

351 Although the default values for the IFR of SARS-CoV-2 and the average lag time from infection to
352 death on the web interface are somewhat arbitrary (and are meant to be adjusted by the user), they both
353 fall on the range of most estimated values for these parameters from other research (e.g., O’Driscoll et al.
354 2020; Wilson et al. 2020), and result in estimated daily new SARS-CoV-2 infections that are qualitatively
355 and/or quantitatively similar to other leading resources (e.g., Gu 2020; Reiner et al. 2020).




Figure 5. The *covid19.Explorer* web interface (<https://covid19-explorer.org>) showing estimated cumulative SARS-CoV-2 infections among states under the same IFR model as Figures 1 – 4.

356 2 RESULTS

357 The purpose of this article is to describe a software tool, which I have largely done in the preceding
358 section. Here, I will attempt to highlight some results and insights that can be obtained by users via
359 interaction with the *covid19.Explorer* R package or web application.

360 2.1 Herd immunity and the cumulative proportion of the population infected

361 The question of cumulative percent infected is relevant to the (unnecessarily controversial) concept of
362 ‘herd immunity’ (Randolph and Barreiro, 2020). The herd immunity threshold (HIT), whether reached
363 via natural infection or vaccination, is typically defined as the proportion of the population that must
364 be immune in order to cause the basic reproductive number of the virus (R_t) to fall below 1.0, absent
365 mitigations (Anderson and May, 1985). When R_t has fallen below 1.0, daily new infections should
366 progressively decline.

367 The HIT is normally estimated by taking the reproductive number when 100% of the population is
368 susceptible (i.e., when a new disease emerges, R_0), and computing $1 - 1/R_0$. For SARS-CoV-2 various
369 values of R_0 have been represented in the literature, from as low as around $R_0 = 2.4$ (e.g., D’Arienzo and




Figure 6. a) Observed daily COVID-19 deaths and an assumed model of IFR. b) Estimated cumulative SARS-CoV-2 infections (green), cases (blue), and deaths (red), as a percentage of the total population of the state.

370 Coniglio 2020), to as high as about $R_0 = 5.8$ (e.g., Ke et al. 2020). A value of R_0 equal to 3.0, for example,
371 would imply that herd immunity should be reached after $1 - 1/3$ or around 67% of the population has
372 acquired immunity through natural infection or vaccination (not accounting for waning acquired immunity
373 from natural infection, which some studies have indicated for SARS-CoV-2; e.g., Long et al. 2020).

374 The *covid19.Explorer* R package and web application can be used to evaluate the proportion of
375 individuals in the total population that have been potentially infected with SARS-CoV-2, given our model
376 for COVID-19 IFR through time. Figure 6 shows cumulative estimated SARS-CoV-2 infections as a
377 fraction of the total population for the U.S. state of Texas, using the same IFR model as in Figures 1, 2, 3,
378 and 4.

379 Though Figure 6 suggests that perhaps around 25-30% of the population in Texas has already been
380 infected, users should keep in mind that this result is entirely dependent on how we decided to specify our
381 model of IFR through time! Likewise, though this fraction is considerable, it is still well below the level
382 of infection (e.g., 67%) required to achieve herd immunity given the majority of published estimates for
383 R_0 of SARS-CoV-2. It may be worth noting that some authors have pointed out that the herd immunity
384 threshold from a natural epidemic could be considerably lower than the $1 - 1/R_0$ level expected for
385 random vaccination (e.g., Britton et al. 2020; Gomes et al. 2020). This is an intriguing possibility, and
386 one that could be qualitatively examined with some of the tools of the *covid19.Explorer* package.

387 2.2 Computing a plausible range of infection numbers

388 A relatively simple extension of the infection estimation method, described above, is to admit uncertainty
389 about the specific value of the infection fatality rate at any particular time during the pandemic, and then
390 measure the sensitivity of our prediction to a *wide range* of different values for IFR.

391 This is a potentially valuable exercise, precisely because the question of the IFR for COVID-19 has
392 been the subject of considerable controversy and confusion (e.g., Vermund and Pitzer 2020). This model




Figure 7. a) Confirmed COVID-19 deaths and a plausible range of scenarios for the evolution of SARS-CoV-2 infection fatality rate (IFR) through time. b) A corresponding plausible range of daily new infections, under our model, for the U.S. state of Louisiana.

393 can be design to accommodate an assumption of broad uncertainty in IFR early during the pandemic, with
394 both decreasing IFR, as well as decreasing *uncertainty* in IFR, towards the present. This is illustrated for
395 data from the U.S. state of Louisiana in Figure 7.

396 It should be noted that although the shaded region around the mean number of daily or cumulative
397 infections in Figure 7 looks like a confidence band, it would only be valid to consider it as such if our high
398 and low values of the IFR through time represented a *confidence interval* around the true infection fatality
399 rate (and, even then, this confidence interval would only take into account one source of uncertainty
400 about the real daily number of infections – the IFR). As an increasing number of studies are able to
401 provide us with better and better estimates of the IFR of SARS-CoV-2 throughout this pandemic (e.g.,
402 O’Driscoll et al. 2020) it may be possible to parameterize this model in a way that genuinely accounts for
403 changing uncertainty in the value of IFR through time in the U.S. pandemic. For the time being, however,
404 I recommend employing the method as a heuristic approach to obtaining a credible range of daily new or
405 cumulative SARS-CoV-2 infections under an explicit model for the United States or any particular U.S.
406 jurisdiction.

407 **2.3 Comparing daily and cumulative infections between states**

408 Another straightforward extension of our above-described model involves directly comparing daily (or
409 cumulative) infections between states.

410 This, likewise, could be a useful activity because many readers have undoubtedly observed how
411 common it has become for (particularly) popular press sources to attribute different infection dynamics
412 in different states to one public health intervention or another. This attribution may be valid in many
413 instances, but is often confounded by varying infection dynamics through time in the different states being
414 compared. In general, evaluation of non-pharmaceutical interventions on the spread of SARS-CoV-2 (e.g.,
415 Bennett 2021; Liu et al. 2021) has been both very difficult and problematic. In Figure 8, I compare the




Figure 8. Daily confirmed COVID-19 deaths (a) or estimated SARS-CoV-2 infections (b) in the U.S. states of California vs. Florida.

416 daily confirmed deaths and estimated infections between the U.S. states of California and Florida.

417 This plotting method obviously shares *all* of the assumptions of our infection estimator, and (just like
418 our method for visualizing the geographic dynamics of the pandemic across all U.S. states) requires that
419 we use the same IFR model for each state. Since the daily and cumulative number of infections scales
420 with population size, valid state-to-state comparisons really only make sense if done on a per-capita basis
421 (e.g., infections or deaths / 1M population), just as shown here in Figure 8.

422 2.4 COVID-19 mortality and age

423 Lastly, in addition to modeling the number of SARS-CoV-2 infections through time, the *covid19.Explorer*
424 package can be used to analyze and graph COVID-19 deaths by age and sex, as well as excess mortality
425 by age and jurisdiction.

426 This functionality, too, can sometimes lead to valuable insights. For instance, it was widely predicted
427 by media and public health experts that school and college reopening in the fall was likely to increased
428 SARS-CoV-2 infections and increased COVID-19 deaths among U.S. children and young people, as well
429 as increased SARS-CoV-2 transmission in the community (e.g., Bansal et al. 2020). In my opinion, the
430 minimum standard of evidence required to establish that reopening of colleges and universities for the
431 fall semester of 2020 had led to increased community transmission overall (remembering the adolescents
432 and young adults live in communities, regardless of whether they are on campus or at home) would be
433 increased SARS-CoV-2 infections of college-aged youth, as a proportion of all infections, during the fall
434 than in spring or summer.

435 In fact, and keeping in mind that COVID-19 deaths are always a better (though lagging) indicator of
436 SARS-CoV-2 infections than observed cases, CDC mortality data show precisely the opposite pattern.
437 Figure 9 gives the weekly COVID-19 deaths over all ages (in panel a) and for 15-24 year olds (in panel b).
438 We see that although the highest peaks of weekly COVID-19 deaths in the general population occurred in
439 the spring of 2020 and the fall/winter of 2020/21, peak deaths among 15-24 are similar between summer
440 and fall, and much higher (as a proportion of all COVID-19 deaths) during the summer – precisely
441 when schools and colleges were out of session for all students. This implies in turn that adolescents and
442 college-aged adults may have been more likely to become infected with SARS-CoV-2 when schools were




Figure 9. Weekly confirmed COVID-19 deaths for (a) all ages; and (b) individuals aged 15-24 years old in the U.S.

443 in summer recess then when they returned to campus in the fall.

444 **3 DISCUSSION**

445 The SARS-CoV-2 global pandemic of 2020 and 2021 has upended economies and civil society worldwide.
446 With widespread vaccination campaigns underway in many countries, and particularly in the United
447 States, the COVID-19 pandemic may *finally* be in its waning days (even if SARS-CoV-2 ultimate becomes
448 endemic and never entirely goes away, e.g., Shaman and Galanti 2020). Nonetheless, understanding
449 the temporal and geographical dynamics of SARS-CoV-2 infections and COVID-19 deaths remains a
450 critically important endeavor. The COVID-19 pandemic is neither the first, nor will it be the last, global
451 respiratory virus pandemic (Saunders-Hastings and Krewski, 2016; Piret and Boivin, 2021). Lessons
452 learned from this pandemic will be of substantial and lasting consequence in managing or failing to
453 manage future public health emergencies.

454 In this article, I present an accessible tool – the *covid19.Explorer* R package and corresponding web
455 application – that is designed to be used to model U.S. SARS-CoV-2 infections through time, to understand
456 the differences in epidemic dynamics between states and jurisdictions, to visualize the geographic progress
457 of infection among U.S. states, to graph confirmed COVID-19 deaths by age and sex, and to compute and
458 visualize excess mortality by age and jurisdiction.

459 Given the impact the SARS-CoV-2 pandemic has had on almost all of our daily lives over the
460 past year, most readers of this article will know (or will be unsurprised to learn) that many other
461 software tools and web-based applications have been developed to help visualize or better understand the
462 temporal or geographic dynamics of COVID-19 in the United States. I nonetheless believe, however, that
463 *covid19.Explorer* application, which has now been online (in one form or another) for nearly seven months,
464 contains a number of different functionalities and graphics not readily available in other competing tools.

465 Firstly, no other software or web application, to my knowledge, lets the user build a *custom model* for

466 the evolution of infection fatality rate (IFR) through time. This facility, offered by *covid19.Explorer*, allows
467 the scientists and lay people that interact with the software to design their own parameter function (be it
468 based on specific hypothesis about IFR through time, or external information – e.g., from seroprevalence
469 studies – about the value of IFR for SARS-CoV-2 at a specific time and place) that will then be used to
470 estimate infections under the model. Likewise, the tool allows *covid19.Explorer* users to progressively
471 adjust the parameter values and other assumptions of this model and see how their results change in turn.

472 Secondly, multiple *visualization methods* of the *covid19.Explorer* R package and webpage are simply
473 *not represented* in other software packages. For instance, I have never observed a graph similar to that
474 of Figure 4 of this article in a publication or popular media source (other than those reporting on this
475 application). Similarly, while it is extremely common to see graphs in the *New York Times* or other media
476 showing the number of *confirmed* COVID-19 cases per day (the part above the ‘waterline’ in our iceberg
477 graph of Figure 3), I have likewise *never* once seen a similar plot giving an estimate of the daily number
478 of unobserved infections (below it).

479 Lastly, the *covid19.Explorer* package is completely transparent and open source. It pulls its data
480 directly from public, government repositories. All model assumptions (even those not explicitly described
481 in this paper) are readily identified from the software source code of the package functions.

482 Even if the SARS-CoV-2 pandemic eventually becomes a distant memory, I hope that this tool (which
483 I plan to make available indefinitely) will continue to be of use to scientists and educated lay people
484 interested in the learning from the successes and failures of policy during the 2020/21 pandemic – perhaps
485 to ensure that there are more of the former and fewer of the latter in our next global infectious disease
486 pandemic.

487 ACKNOWLEDGMENTS

488 This work is inspired by the brilliant, independent COVID-19 research of Y. Gu; by the calm and
489 thoughtful public health insights of J. Allen, F. Balloux, M. Gandhi, A. Munro, and others like them; by
490 my wife, E. Lu, who has been forced (due to stay at home orders and other restrictions) to suffer much
491 more of my research struggles than she would under normal circumstances; and by the persistent failure
492 of governments, public officials, and private citizens worldwide to make evidence-based decisions that
493 take into account real risks and collateral harms, in favor of unscientific performative public health theater
494 designed to abate fear. The article was improved greatly over earlier versions due to numerous helpful
495 comments from N. Dimonaco, A. Kala, and one anonymous reviewer.

496 REFERENCES

- 497 Al-Sadeq, D. W. and Nasrallah, G. K. (2020). The incidence of the novel coronavirus SARS-CoV-2
498 among asymptomatic patients: A systematic review. *International Journal of Infectious Diseases*,
499 98:372–380.
- 500 Ammar, R. (2019). *randomcolor: Generate Attractive Random Colors*. R package version 1.1.0.1.
- 501 Anderson, R. M. and May, R. M. (1985). Vaccination and herd immunity to infectious diseases. *Nature*,
502 318(6044):323–329.
- 503 Bansal, S., Carlson, C., and Kraemer, J. (2020). There is no safe way to reopen colleges this fall:
504 Reopening colleges during a pandemic is too dangerous. *Washington Post*.
- 505 Becker, R. A., Wilks, A. R., Brownrigg, R., Minka, T. P., and Deckmyn, A. (2018). *maps: Draw*
506 *Geographical Maps*. R package version 3.3.0.
- 507 Bennett, M. (2021). All things equal? heterogeneity in policy effectiveness against COVID-19 spread in
508 chile. *World Development*, 137:105208.
- 509 Blackburn, J., Yiannoutsos, C. T., Carroll, A. E., Halverson, P. K., and Menachemi, N. (2021). Infection
510 fatality ratios for COVID-19 among noninstitutionalized persons 12 and older: Results of a random-
511 sample prevalence study. *Annals of Internal Medicine*, 174(1):135–136.
- 512 Britton, T., Ball, F., and Trapman, P. (2020). A mathematical model reveals the influence of population
513 heterogeneity on herd immunity to SARS-CoV-2. *Science*, 369(6505):846–849.
- 514 Brown, M., Curiskis, A., French, A., Glickhouse, R., Goldfarb, A., Kodysh, J., Lipton, Z., Luo,
515 D., Malaty-Rivera, J., Mart, M., and et al. (2020). The COVID tracking project by the atlantic.
516 <https://covidtracking.com/>.
- 517 CDC (2021). *COVID-19*.

- 518 Chang, W., Cheng, J., Allaire, J., Sievert, C., Schloerke, B., Xie, Y., Allen, J., McPherson, J., Dipert, A.,
519 and Borges, B. (2021). *shiny: Web Application Framework for R*. R package version 1.6.0.
- 520 Chin, V., Samia, N. I., Marchant, R., Rosen, O., Ioannidis, J. P. A., Tanner, M. A., and Cripps, S. (2020).
521 A case study in model failure? COVID-19 daily deaths and ICU bed utilisation predictions in new york
522 state. *European Journal of Epidemiology*, 35(8):733–742.
- 523 Cleveland, W. S. (1979). Robust locally weighted regression and smoothing scatterplots. *Journal of the*
524 *American Statistical Association*, 74(368):829–836.
- 525 D'Arienzo, M. and Coniglio, A. (2020). Assessment of the SARS-CoV-2 basic reproduction number, r_0 ,
526 based on the early phase of COVID-19 outbreak in italy. *Biosafety and Health*, 2(2):57–59.
- 527 Fan, G., Yang, Z., Lin, Q., Zhao, S., Yang, L., and He, D. (2020). Decreased case fatality rate of
528 COVID-19 in the second wave: A study in 53 countries or regions. *Transboundary and Emerging*
529 *Diseases*.
- 530 Gomes, M. G. M., Aguas, R., Corder, R. M., King, J. G., Langwig, K. E., Souto-Maior, C., Carneiro, J.,
531 Ferreira, M. U., and Penha-Gonçalves, C. (2020). Individual variation in susceptibility or exposure to
532 SARS-CoV-2 lowers the herd immunity threshold.
- 533 Gonzalez-Reiche, A. S., Hernandez, M. M., Sullivan, M. J., Ciferri, B., Alshammary, H., Obla, A., Fabre,
534 S., Kleiner, G., Polanco, J., Khan, Z., Albuquerque, B., van de Guchte, A., Dutta, J., Francoeur, N.,
535 Melo, B. S., Oussenko, I., Deikus, G., Soto, J., Sridhar, S. H., Wang, Y.-C., Twyman, K., Kasarskis, A.,
536 Altman, D. R., Smith, M., Sebra, R., Aberg, J., Krammer, F., García-Sastre, A., Luksza, M., Patel, G.,
537 Paniz-Mondolfi, A., Gitman, M., Sordillo, E. M., Simon, V., and van Bakel, H. (2020). Introductions
538 and early spread of SARS-CoV-2 in the new york city area. *Science*, page eabc1917.
- 539 Gu, Y. (2020). COVID-19 projections using machine learning. <https://covid19-projections.com>.
- 540 Huynen, M. M., Martens, P., Schram, D., Weijenberg, M. P., and Kunst, A. E. (2001). The impact of heat
541 waves and cold spells on mortality rates in the dutch population. *Environmental Health Perspectives*,
542 109(5):463–470.
- 543 Ioannidis, J. P., Cripps, S., and Tanner, M. A. (2020). Forecasting for COVID-19 has failed. *International*
544 *Journal of Forecasting*.
- 545 James, L. P., Salomon, J. A., Buckee, C. O., and Menzies, N. A. (2021). The use and misuse of
546 mathematical modeling for infectious disease policymaking: Lessons for the COVID-19 pandemic.
547 *Medical Decision Making*, page 0272989X2199039.
- 548 Johns Hopkins University (2020). Johns hopkins university center for systems science and engineering
549 covid-19 dashboard.
- 550 Ke, R., Sanche, S., Romero-Severson, E., and Hengartner, N. (2020). Estimating the reproductive number
551 r_0 of SARS-CoV-2 in the united states and eight european countries and implications for vaccination.
- 552 Kompaniyets, L., Goodman, A. B., Belay, B., Freedman, D. S., Sucusky, M. S., Lange, S. J., Gundlapalli,
553 A. V., Boehmer, T. K., and Blanck, H. M. (2021). Body mass index and risk for COVID-19–related
554 hospitalization, intensive care unit admission, invasive mechanical ventilation, and death — united
555 states, march–december 2020. *MMWR. Morbidity and Mortality Weekly Report*, 70(10):355–361.
- 556 Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D., and Lessler, J. (2020). Variation in false-
557 negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since
558 exposure. *Annals of Internal Medicine*, 173(4):262–267.
- 559 Levin, A. T., Meyerowitz-Katz, G., Owusu-Boaitey, N., Cochran, K. B., and Walsh, S. P. (2020). Assessing
560 the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and
561 public policy implications.
- 562 Liu, Y., , Morgenstern, C., Kelly, J., Lowe, R., and Jit, M. (2021). The impact of non-pharmaceutical
563 interventions on SARS-CoV-2 transmission across 130 countries and territories. *BMC Medicine*, 19(1).
- 564 Lone, N. I., McPeake, J., Stewart, N. I., Blayney, M. C., Seem, R. C., Donaldson, L., Glass, E., Haddow,
565 C., Hall, R., Martin, C., Paton, M., Smith-Palmer, A., Kaye, C. T., and Puxty, K. (2021). Influence of
566 socioeconomic deprivation on interventions and outcomes for patients admitted with COVID-19 to
567 critical care units in scotland: A national cohort study. *The Lancet Regional Health - Europe*, 1:100005.
- 568 Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J.,
569 Su, K., Zhang, F., Gong, J., Wu, B., Liu, X.-M., Li, J.-J., Qiu, J.-F., Chen, J., and Huang, A.-L. (2020).
570 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine*,
571 26(8):1200–1204.
- 572 Neuwirth, E. (2014). *RColorBrewer: ColorBrewer Palettes*. R package version 1.1-2.

- 573 O’Driscoll, M., Santos, G. R. D., Wang, L., Cummings, D. A. T., Azman, A. S., Paireau, J., Fontanet, A.,
574 Cauchemez, S., and Salje, H. (2020). Age-specific mortality and immunity patterns of SARS-CoV-2.
575 *Nature*, 590(7844):140–145.
- 576 Oran, D. P. and Topol, E. J. (2020). Prevalence of asymptomatic SARS-CoV-2 infection. *Annals of*
577 *Internal Medicine*, 173(5):362–367.
- 578 Perrier, V., Meyer, F., and Granjon, D. (2021). *shinyWidgets: Custom Inputs Widgets for Shiny*. R package
579 version 0.5.7.
- 580 Piret, J. and Boivin, G. (2021). Pandemics throughout history. *Frontiers in Microbiology*, 11.
- 581 R Core Team (2020). *R: A Language and Environment for Statistical Computing*. R Foundation for
582 Statistical Computing, Vienna, Austria.
- 583 Randolph, H. E. and Barreiro, L. B. (2020). Herd immunity: Understanding COVID-19. *Immunity*,
584 52(5):737–741.
- 585 Reiner, B., Barber, R., and Murray, C. J. L. (2020). Modeling COVID-19 scenarios for the united states.
586 *Nature Medicine*, 27(1):94–105.
- 587 Revell, L. J. (2012). phytools: An r package for phylogenetic comparative biology (and other things).
588 *Methods in Ecology and Evolution*, 3:217–223.
- 589 Rinaldi, G. and Paradisi, M. (2020). An empirical estimate of the infection fatality rate of COVID-19
590 from the first italian outbreak.
- 591 Roques, L., Klein, E. K., Papaix, J., Sar, A., and Soubeyrand, S. (2020). Using early data to estimate the
592 actual infection fatality ratio from COVID-19 in france. *Biology*, 9(5):97.
- 593 Rosenberg, E. S., Dufort, E. M., Blog, D. S., Hall, E. W., Hoefler, D., Backenson, B. P., Muse, A. T.,
594 Kirkwood, J. N., George, K. S., Holtgrave, D. R., Hutton, B. J., Zucker, H. A., Anand, M., Kaufman,
595 A., Kuhles, D., Maxted, A., Newman, A., Pulver, W., Smith, L., Sommer, J., White, J., Dean, A.,
596 Derbyshire, V., Egan, C., Fuschino, M., Griesemer, S., Hull, R., Lamson, D., Laplante, J., McDonough,
597 K., Mitchell, K., Musser, K., Nazarian, E., Popowich, M., Taylor, J., Walsh, A., Amler, S., Huang, A.,
598 Recchia, R., Whalen, E., Lewis, E., Friedman, C., Carrera, S., Eisenstein, L., DeSimone, A., Morne, J.,
599 Johnson, M., Navarette, K., Kumar, J., Ostrowski, S., Mazeau, A., Dreslin, S., Yates, N., Greene, D.,
600 Heslin, E., Lutterloh, E., Rosenthal, E., Barranco, M., Anand, M., Kaufman, A., Kuhles, D., Maxted,
601 A., Newman, A., Pulver, W., Smith, L., Sommer, J., White, J., Dean, A., Derbyshire, V., Egan, C.,
602 Fuschino, M., Griesemer, S., Hull, R., Lamson, D., Laplante, J., McDonough, K., Mitchell, K., Musser,
603 K., Nazarian, E., Popowich, M., Taylor, J., Walsh, A., Amler, S., Huang, A., Recchia, R., Whalen, E.,
604 Lewis, E., Friedman, C., Carrera, S., Eisenstein, L., DeSimone, A., Morne, J., Johnson, M., Navarette,
605 K., Kumar, J., Ostrowski, S., Mazeau, A., Dreslin, S., Yates, N., Greene, D., Heslin, E., Lutterloh, E.,
606 Rosenthal, E., and and, M. B. (2020). COVID-19 testing, epidemic features, hospital outcomes, and
607 household prevalence, new york state—march 2020. *Clinical Infectious Diseases*, 71(8):1953–1959.
- 608 RStudio Team (2020). *RStudio: Integrated Development Environment for R*. RStudio, PBC., Boston, MA.
- 609 Saunders-Hastings, P. and Krewski, D. (2016). Reviewing the history of pandemic influenza: Understand-
610 ing patterns of emergence and transmission. *Pathogens*, 5(4):66.
- 611 Shaman, J. and Galanti, M. (2020). Will SARS-CoV-2 become endemic? *Science*, 370(6516):527–529.
- 612 Smith, M. D. and Wesselbaum, D. (2020). COVID-19, food insecurity, and migration. *The Journal of*
613 *Nutrition*, 150(11):2855–2858.
- 614 Streeck, H., Schulte, B., Kümmerer, B. M., Richter, E., Höller, T., Fuhrmann, C., Bartok, E., Dolscheid-
615 Pommerich, R., Berger, M., Wessendorf, L., Eschbach-Bludau, M., Kellings, A., Schwaiger, A.,
616 Coenen, M., Hoffmann, P., Stoffel-Wagner, B., Nöthen, M. M., Eis-Hübinger, A. M., Exner, M.,
617 Schmithausen, R. M., Schmid, M., and Hartmann, G. (2020). Infection fatality rate of SARS-CoV2 in
618 a super-spreading event in germany. *Nature Communications*, 11(1).
- 619 Velavan, T. P. and Meyer, C. G. (2020). The COVID-19 epidemic. *Tropical Medicine & International*
620 *Health*, 25(3):278–280.
- 621 Vermund, S. H. and Pitzer, V. E. (2020). Asymptomatic transmission and the infection fatality risk for
622 COVID-19: Implications for school reopening. *Clinical Infectious Diseases*.
- 623 Weinberger, D. M., Chen, J., Cohen, T., Crawford, F. W., Mostashari, F., Olson, D., Pitzer, V. E., Reich,
624 N. G., Russi, M., Simonsen, L., Watkins, A., and Viboud, C. (2020). Estimation of excess deaths
625 associated with the COVID-19 pandemic in the united states, march to may 2020. *JAMA Internal*
626 *Medicine*.
- 627 Wilson, N., Kvalsvig, A., Barnard, L. T., and Baker, M. G. (2020). Case-fatality risk estimates for

- 628 COVID-19 calculated by using a lag time for fatality. *Emerging Infectious Diseases*, 26(6).
- 629 Wong, G., , Bi, Y.-H., Wang, Q.-H., Chen, X.-W., Zhang, Z.-G., Yao, Y.-G., , , , , and and (2020).
630 Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important?
631 *Zoological Research*, 41(3):213–219.
- 632 Wu, S. L., Mertens, A., Crider, Y. S., Nguyen, A., Pokpongkiat, N. N., Djajadi, S., Seth, A., Hsiang, M. S.,
633 Colford, J. M., Reingold, A., Arnold, B. F., Hubbard, A., and Benjamin-Chung, J. (2020). Substantial
634 underestimation of SARS-CoV-2 infection in the united states due to incomplete testing and imperfect
635 test accuracy.
- 636 Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., Wang, Y.,
637 Pan, S., Zou, X., Yuan, S., and Shang, Y. (2020). Clinical course and outcomes of critically ill patients
638 with SARS-CoV-2 pneumonia in wuhan, china: a single-centered, retrospective, observational study.
639 *The Lancet Respiratory Medicine*, 8(5):475–481.